Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Biotech Company QLT Reworks Visudyne Deal With Novartis – Regains US Rights

By Pharmaceutical Processing | October 19, 2009

Canadian biotechnology company QLT Inc. said Monday it will have all U.S. rights to the eye drug Visudyne after reworking a marketing agreement with Novartis AG. Starting Jan. 1, QLT will have exclusive U.S. rights to Visudyne, a treatment for “wet” age-related macular degeneration, which is a common cause of blindness. Novartis, a Swiss drugmaker, will have the right to make and sell the drug in all other countries. It will pay QLT a 20 percent royalty on all sales until Dec. 31, 2014. After that, QLT will get a 16 percent royalty until the end of 2019. Visudyne is one of QLT’s two main products. The other is Eligard, a treatment for the symptoms of prostate cancer. QLT sold the rights to Eligard earlier this month, when it sold its entire U.S. business, although it will still receive royalties on Eligard sales. Since early 2008, QLT has been streamlining its business to focus on Visudyne. Sales of the drug sales have been hurt by the approval of rival products like Roche’s Lucentis. Due to a restructuring in 2008, Novartis no longer has a specific sales force for eye drugs. QLT said Visudyne sales fell 34 percent in 2008.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE